Esperion Therapeutis.Inc. buy Piper Sandler
Start price
25.11.25
/
50%
€3.00
Target price
25.11.26
€7.81
Performance (%)
-7.70%
Price
10.08.26
€2.77
Summary
This prediction is currently active. With a performance of -7.70%, the BUY prediction for Esperion Therapeutis.Inc. by Piper_Sandler is down slightly. This prediction currently runs until 25.11.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 0.000% | 0.000% |
| iShares Core DAX® | 0.625% | 4.952% |
| iShares Nasdaq 100 | 1.160% | -1.160% |
| iShares Nikkei 225® | 2.356% | -1.354% |
| iShares S&P 500 | 0.631% | 1.380% |
Comments by Piper_Sandler for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat